SCHEMBL7065256

SCHEMBL7065256

O=C(CCCN1CCN(C(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc2c(c1)CNCCC2

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.48
DRD2 P14416 6/20 0.47
DRD3 P35462 5/20 0.47
DRD4 P21917 4/20 0.47
MCHR1 Q99705 4/20 0.47
ACHE P22303 3/20 0.47
CYP2D6 P10635 1/20 0.46
ADRA1A P35348 1/20 0.46
ADRA1B P35368 1/20 0.46
HTR2A P28223 3/20 0.45
HTR7 P34969 3/20 0.45
HTR1A P08908 2/20 0.45
HTR2C P28335 1/20 0.45
HRH1 P35367 1/20 0.45
HTR2B P41595 1/20 0.45
SLC18A3 Q16572 1/20 0.43
SIGMAR1 Q99720 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6914762 0.91 ACHE (0.54) DRD2DRD3DRD4MCHR1ACHE
SCHEMBL5578259 0.89 MCHR1 (0.57) TSHRDRD2DRD3DRD4MCHR1
Hydrochloric Acid SCHEMBL5578288 0.88 MCHR1 (0.56) TSHRDRD2DRD3DRD4MCHR1
SCHEMBL6914709 0.88 ACHE (0.52) DRD2DRD3DRD4MCHR1ACHE
SCHEMBL6916872 0.86 ACHE (0.60) TSHRDRD2DRD3DRD4MCHR1
Hydrochloric Acid SCHEMBL5578325 0.84 DRD3 (0.45) DRD2DRD3ACHEHTR1AHTR2C
Trifluoroacetic Acid SCHEMBL6800741 0.84 MCHR1 (0.54) TSHRDRD2DRD3DRD4MCHR1
SCHEMBL6918181 0.81 ACHE (0.59) DRD3MCHR1ACHEADRA1AHTR1A
SCHEMBL5578077 0.79 MCHR1 (0.67) DRD2DRD3DRD4MCHR1ACHE
Hydrochloric Acid SCHEMBL5578192 0.78 MCHR1 (0.66) DRD2DRD3DRD4MCHR1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063699-A1 Gpr14 antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-01 US disclosed
EP-1310490-A1 GPR14 ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063699-A1 Gpr14 antagonist GPR142, GPR139, GPR4 TSHR 1026/4885DRD2 329/4885DRD3 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.